Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863681 · ClinicalTrials.gov registry record · Phase 3
BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 396
- Enrollment target
NCT00863681: Completed Phase 3 study, sponsored by Bayer.
NCT00863681 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 396 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00863681, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 396 participants
- Enrollment target
Study Summary
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
Primary Outcome
Analyses of drug-related TEAEs were based on the assessment of causal relationship to study medication.
Interventions
- DRUG Riociguat (BAY63-2521)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2009-03-12 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 3 |
What the finished NCT00863681 record still lists
NCT00863681 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 1 intervention - of which Riociguat (BAY63-2521) is the first listed.
NCT00863681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00863681 about?
NCT00863681 is a clinical study titled "BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension". Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.
What is the current status of trial NCT00863681?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 396 participants. The study started on 2009-03-12. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT00863681?
The interventions under investigation include: Riociguat (BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT00863681?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00863681's enrollment target sits among peer trials
396 964th of 2000 higher than 1,036 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI